HC Wainwright reissued their buy rating on shares of Entera Bio (NASDAQ:ENTX – Free Report) in a research note published on Friday, Benzinga reports. They currently have a $10.00 price target on the stock.
Entera Bio Stock Down 5.5 %
Shares of Entera Bio stock opened at $1.90 on Friday. The firm has a market cap of $67.99 million, a PE ratio of -6.79 and a beta of 1.57. The business has a 50-day moving average price of $1.77 and a 200 day moving average price of $1.95. Entera Bio has a twelve month low of $0.52 and a twelve month high of $3.35.
Entera Bio (NASDAQ:ENTX – Get Free Report) last announced its earnings results on Friday, August 9th. The company reported ($0.06) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.06). The business had revenue of $0.06 million for the quarter. On average, sell-side analysts expect that Entera Bio will post -0.23 EPS for the current year.
Institutional Trading of Entera Bio
About Entera Bio
Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.
Read More
- Five stocks we like better than Entera Bio
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- TJX Stock: A Buying Opportunity Before the Holiday Rush
- The 3 Best Blue-Chip Stocks to Buy Now
- Micron’s Blowout Results Pave the Way for Seagate’s Stock Surge
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- Zeta Global’s AI Cloud: Your Secret Weapon for Massive Growth
Receive News & Ratings for Entera Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entera Bio and related companies with MarketBeat.com's FREE daily email newsletter.